ABSTRACT
Importance Vaping has become an increasingly common method for consuming nicotine and cannabis, a trend potentially influenced by e-cigarette marketing. However, little is known about the influence of e-cigarette marketing on cannabis vaping behaviors.
Objective To examine the associations between e-cigarette marketing exposure and nicotine and cannabis vaping behaviors among adults.
Design, Setting, and Participants This cross-sectional study included a U.S. nationally representative sample of adults (≥18 years) from the Wave 6 survey of the Population Assessment of Tobacco and Health (PATH) Study, conducted from March to November 2021.
Exposure Past 30-day e-cigarette marketing exposure (overall and by ten marketing channels).
Main Outcomes and Measures Past 30-day vaping behavior (sole- and dual-vaping of nicotine and cannabis) overall and stratified by age.
Results The study included 30,516 respondents (48.0% male and 63.9% non-Hispanic White). Overall, 52.0% of respondents reported past 30-day e-cigarette marketing exposure, and 89.8%, 5.6%, 3.2%, and 1.4% reported no vaping, sole-nicotine vaping, sole-cannabis vaping, and dual-vaping, respectively. Multinominal logistic regression results show exposure to e-cigarette marketing was associated with increased odds of reporting sole-cannabis vaping versus no vaping (adjusted risk ratio [aRR], 1.31; 95% confidence interval [CI], 1.09-1.57) and dual-vaping versus no vaping (aRR, 1.26; 95% CI, 1.01-1.57). Stratification analysis found these associations among those aged 18-24 and 25-34 years but not older adults (≥35 years). Those exposed to e-cigarette marketing also had increased odds of reporting sole-cannabis vaping versus sole-nicotine vaping (aRR, 1.28; 95% CI, 1.04-1.58). Stratification analysis found this association only among those aged 18-24 years. E-cigarette marketing exposure via several channels (retail stores, billboards, events, newspapers/magazines) was associated with increased odds of reporting sole-cannabis vaping.
Conclusions and Relevance E-cigarette marketing exposure was only associated with sole-cannabis vaping and dual-vaping, not sole-nicotine vaping among U.S. adults. Such associations were mainly driven by young adults aged 18-24 and 25-35 years and were found for multiple marketing channels. Greater restrictions on tobacco marketing may have reduced the influence of e-cigarette marketing on nicotine vaping, while gaps in such marketing restrictions for cannabis may contribute to continued influence of e-cigarette marketing on cannabis vaping.
Question What is the association between e-cigarette marketing exposure and nicotine and cannabis vaping behaviors among U.S. adults?
Findings In this cross-sectional study of 30,516 adults, those exposed to e-cigarette marketing were about 1.3 times more likely to report sole-cannabis vaping and dual-nicotine and cannabis vaping compared to those not exposed to e-cigarette marketing. Such associations were not found for sole-nicotine vaping.
Meaning Greater restrictions on tobacco marketing may have reduced the influence of e-cigarette marketing on nicotine vaping, while gaps in marketing restrictions for cannabis may contribute to the continued influence of e-cigarette marketing on cannabis vaping.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
JCS is supported by the Pathway to Independence Award in Tobacco Regulatory Science from NCI/FDA (R00CA242589) and Penn/Rutgers TCORS (U54CA229973). AG is supported by the National Center for Advancing Translational Sciences of the National Institutes of Health (TL1TR003019). MBM holds an Innovation in Regulatory Science Award from the Burroughs Wellcome Fund.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All data produced are available online at https://www.icpsr.umich.edu/web/NAHDAP/studies/36498
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Disclosure/Funding Sources: None.
Data sharing agreement: Stata codes for analyzing the data may be available upon request.
Funding statement: JCS is supported by the Pathway to Independence Award in Tobacco Regulatory Science from NCI/FDA (R00CA242589) and Penn/Rutgers TCORS (U54CA229973). AG is supported by the National Center for Advancing Translational Sciences of the National Institutes of Health (TL1TR003019). MBM holds an Innovation in Regulatory Science Award from the Burroughs Wellcome Fund.
Data Availability
All data produced are available online at https://www.icpsr.umich.edu/web/NAHDAP/studies/36498
